184 related articles for article (PubMed ID: 28206956)
21. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2.
Kim JH; Park SG; Song SY; Kim JK; Sung JH
Cell Death Dis; 2013 Apr; 4(4):e588. PubMed ID: 23579275
[TBL] [Abstract][Full Text] [Related]
22. MKNK2 enhances chemoresistance of ovarian cancer by suppressing autophagy via miR-125b.
Wang J; Da C; Su Y; Song R; Bai Z
Biochem Biophys Res Commun; 2021 Jun; 556():31-38. PubMed ID: 33836345
[TBL] [Abstract][Full Text] [Related]
23. Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes.
Ahmad A; Zhang W; Wu M; Tan S; Zhu T
Genes Genomics; 2018 Mar; 40(3):243-251. PubMed ID: 29892795
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-181 Functions as an Antioncogene and Mediates NF-κB Pathway by Targeting RTKN2 in Ovarian Cancers.
Lin Z; Li D; Cheng W; Wu J; Wang K; Hu Y
Reprod Sci; 2019 Aug; 26(8):1071-1081. PubMed ID: 30309296
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma.
Wan HY; Guo LM; Liu T; Liu M; Li X; Tang H
Mol Cancer; 2010 Jan; 9():16. PubMed ID: 20102618
[TBL] [Abstract][Full Text] [Related]
26. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells.
Grumont RJ; Rourke IJ; O'Reilly LA; Strasser A; Miyake K; Sha W; Gerondakis S
J Exp Med; 1998 Mar; 187(5):663-74. PubMed ID: 9480976
[TBL] [Abstract][Full Text] [Related]
27. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
28. Evidence for miR-17-92 and miR-134 gene cluster regulation of ovarian cancer drug resistance.
Zhu H; Yang SY; Wang J; Wang L; Han SY
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2526-31. PubMed ID: 27383301
[TBL] [Abstract][Full Text] [Related]
29. Transcription factor ELK1 accelerates aerobic glycolysis to enhance osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade.
Zhang Q; Wu J; Zhang X; Cao L; Wu Y; Miao X
Aging (Albany NY); 2021 Feb; 13(5):6804-6819. PubMed ID: 33621196
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
31. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
32. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
33. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
34. BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferation via regulation of NF-κB1.
Zhang ZX; Liu ZQ; Jiang B; Lu XY; Ning XF; Yuan CT; Wang AL
Biochem Biophys Res Commun; 2015 Sep; 465(2):225-31. PubMed ID: 26248136
[TBL] [Abstract][Full Text] [Related]
35. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
36. MiR-185-5p suppresses HBV gene expression by targeting ELK1 in hepatoma carcinoma cells.
Fan HX; Feng YJ; Zhao XP; He YZ; Tang H
Life Sci; 2018 Nov; 213():9-17. PubMed ID: 30308183
[TBL] [Abstract][Full Text] [Related]
37. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
38. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
39. MiR-200c and HuR in ovarian cancer.
Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
